An interventional study of Rosuvastatin 5mg and Rosuvastatin 20mg in Arteriosclerosis, Diabetes Mellitus and Lipid Disorder, sponsored by Capital Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-21.
Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment
The aim of this study is to assess whether high intensive statin therapy could regress carotid atherosclerotic plaques as determined by High-Resolution Contrast Enhanced Magnetic Resonance imaging (CE-MRI).
Enrolled patients have a baseline CE-MRI examination for screening carotid atherosclerotic plaques and are randomized to either low dose of Rosuvastatin (5mg) group or high dose of Rosuvastatin (20mg) group. After 26 weeks, all patients received CE-MRI examination again and each pair of baseline and follow-up CE-MRI assessments was analyzed in a blinded fashion. Moreover, lipid level and major adverse cardiovascular events are also evaluated during follow-up.
317 studies on the registry are indexed under Arteriosclerosis; 33 are open to participants now.
This study's planned enrollment of 150 is close to the median of 144 across 182 interventional studies indexed under Arteriosclerosis.
Browse Arteriosclerosis studies →Capital Medical University is the lead sponsor of 283 studies on the registry; 92 are open to participants now.
Counted across the registry records on this site, refreshed daily.
-Patients with coronary artery disease or carotid atherosclerotic plaque or hyperlipideimia or old myocardial infarction
Exclusion Criteria:
low dose Rosuvastatin
Drug: Rosuvastatin 5mg
high dose Rosuvastatin
Drug: Rosuvastatin 20mg
drug intervention
drug intervention
To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI
Time frame: 26 weeks
major adverse cardiovascular events
Time frame: 26 weeks
To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
Time frame: 26 weeks
To evaluate the change from baseline in liver function (AST/ALT) at 26 weeks
Time frame: 26 weeks
To evaluate the change from baseline in renal function (serum creatine) at 26 weeks
Time frame: 26 weeks
To evaluate the change from baseline in creatine kinase at 26 weeks
Time frame: 26 weeks
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Capital Medical University